Paquinimod may have potential therapeutic applications as an S100A8/S100A9 inhibitor, as excessive release of S100A8/S100A9 is associated with the occurrence and development of various inflammatory and autoimmune disorders. Here, S100A9 is linked to Autoimmunity.